Minerva Neurosciences, a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focuses on developing treatments for central nervous system diseases, including roluperidone for schizophrenia and MIN-301 for Parkinson's disease. Founded in 2014, it employs 9 people and co-developed seltorexant for insomnia and major depressive disorder.
NERV filed a patent for "sigma ligand compounds and uses thereof" on Fri, April 26, 2024. The patent was officially published on Thu, November 14, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
